Sponsored content provided by MeiraGTx for educational purposes and reviewed for alignment with the Head & Neck Cancer Alliance mission.
For many head and neck cancer survivors, finishing treatment doesn’t mean the hard part is over. Months or years later, they’re still dealing with xerostomia, the medical term for chronic dry mouth. It’s one of the most common and persistent side effects of radiation therapy, and it doesn’t get the attention it deserves.
Why radiation damages the salivary glands
Radiation is often essential for treating head and neck cancers, but the salivary glands pay a price. The parotid glands in particular are highly sensitive to radiation, and the cells that produce saliva don’t regenerate the way other tissues do. Once damaged, they’re often damaged for good.
Saliva does more than most people realize. It helps you swallow, digest food, speak clearly, taste what you’re eating, and protect your teeth and mouth from infection. When saliva production drops significantly, all of that is affected.
Who this affects
Radiation-induced xerostomia is most common in people treated for:
- Head and neck cancers
- Oropharyngeal cancers
- Cancers involving the oral cavity, throat, or salivary glands
Many patients experience dry mouth during treatment and expect it to improve afterward. For a significant portion of survivors, it doesn’t. They finish treatment, they’re cancer-free, and they’re still dealing with severe dry mouth every day for the rest of their lives.
What it’s actually like to live with
Dry mouth sounds like a minor inconvenience. It isn’t. Patients describe needing water within reach at all times, struggling to eat solid foods, waking up at night from severe mouth dryness, and having difficulty talking for any extended period. Over time, the lack of saliva leads to tooth decay, gum disease, mouth sores, and difficulty eating enough to maintain weight.
These aren’t occasional problems. They’re daily, and they affect everything from social life to nutrition to overall health.
Why current treatments aren’t enough
The options available today are mostly about managing symptoms: sipping water frequently, using saliva substitutes or sprays, chewing sugar-free gum, or taking medications meant to stimulate saliva production. Some patients get partial relief. Many don’t.
None of these treatments repair the underlying damage. The glands are still damaged. The saliva production is still reduced. Patients are often told, frankly, that this is just something they’ll have to live with.
What gene therapy research is exploring
That’s why researchers are looking at a different approach. Saliva secretion depends on water moving through specialized channels in salivary gland cells. One key channel is aquaporin-1 (AQP1), a protein that facilitates that water movement.
Gene therapy being studied for xerostomia works by delivering the AQP1 gene directly to the damaged salivary gland, giving remaining cells the ability to move water even when many saliva-producing cells have been lost. It’s designed as a one-time, locally delivered treatment administered directly to the gland through a minimally invasive procedure. The goal isn’t temporary relief. It’s restoring function at the source.
A survivorship issue worth taking seriously
Xerostomia doesn’t threaten survival, and that’s part of why it often gets overlooked. But for the people living with it, it’s a daily burden that affects how they eat, sleep, speak, and engage with the world around them.
The Head & Neck Cancer Alliance is committed to raising awareness of survivorship challenges like this one, and to supporting patients with the education and resources they need after treatment ends. If you or someone you care about is dealing with chronic dry mouth after head and neck cancer treatment, it’s worth talking to a healthcare provider about what options exist today and what’s being studied.
